id: NEW:pharmacological_treatment_for_antisocial_personality_disorder_to_NEW:aggression_frequency
name: Pharmacological Treatment for Antisocial Personality Disorder â†’ Aggression Frequency
from_node:
  node_id: NEW:pharmacological_treatment_for_antisocial_personality_disorder
  node_name: Pharmacological Treatment for Antisocial Personality Disorder
to_node:
  node_id: NEW:aggression_frequency
  node_name: Aggression Frequency
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Antiepileptic medication (phenytoin) administered to individuals with antisocial personality
  disorder'
- 'Step 2: Phenytoin may modulate neuronal excitability and impulse control pathways'
- 'Step 3: Reduced frequency of aggressive acts observed in prison setting'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: Najat R Khalifa et al. 2020. "Pharmacological interventions for antisocial personality
    disorder.." https://doi.org/10.1002/14651858.CD007667.pub3
  supporting_citations:
  - Additional citations require full-text access - abstract references single unreplicated phenytoin
    study in male prisoners
  - Study conducted in prison setting with 60 participants
  - No standard deviations reported limiting statistical analysis
  doi: 10.1002/14651858.CD007667.pub3
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Very low certainty evidence from a single study (60 participants) suggests phenytoin 300mg/day
  may reduce mean frequency of aggressive acts per week compared to placebo in male prisoners with aggression
  (phenytoin mean=0.33 vs placebo mean=0.51). Evidence quality is insufficient to draw conclusions about
  pharmacological treatment for AsPD.
quantitative_effects:
  sample_size: 60
spatial_variation:
  varies_by_geography: true
  variation_notes: Most studies (10/11) conducted in North America; findings may not generalize to other
    settings
moderators:
- name: comorbid_substance_use
  direction: weakens
  strength: moderate
  description: Many participants presented primarily with substance abuse problems rather than AsPD as
    primary diagnosis, potentially confounding results
- name: study_setting
  direction: strengthens
  strength: weak
  description: Prison setting may provide more controlled environment for medication adherence but limits
    generalizability
structural_competency:
  equity_implications: This review highlights critical structural gaps in mental health research and treatment
    for antisocial personality disorder. The lack of evidence reflects systemic underinvestment in mental
    health research for personality disorders, particularly in carceral settings where AsPD is overrepresented.
    The focus on pharmacological interventions without addressing root causes (adverse childhood experiences,
    socioeconomic factors, lack of community mental health infrastructure) represents a medicalized approach
    that may miss structural determinants. Equity implications include the predominance of male participants
    (90%) and the intersection with criminal justice involvement and substance use disorders.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.350219'
  extraction_confidence: low
  prompt_version: 2.1-canonical-validated
